Heumann, Thatcher
Judkins, Carol
Li, Keyu
Lim, Su Jin
Hoare, Jessica
Parkinson, Rose
Cao, Haihui
Zhang, Tengyi
Gai, Jessica
Celiker, Betul
Zhu, Qingfeng http://orcid.org/0000-0001-7871-3359
McPhaul, Thomas
Durham, Jennifer
Purtell, Katrina
Klein, Rachel
Laheru, Daniel
De Jesus-Acosta, Ana
Le, Dung T. http://orcid.org/0000-0002-2110-7697
Narang, Amol
Anders, Robert http://orcid.org/0000-0002-2363-9072
Burkhart, Richard
Burns, William
Soares, Kevin http://orcid.org/0000-0002-0406-017X
Wolfgang, Christopher
Thompson, Elizabeth
Jaffee, Elizabeth http://orcid.org/0000-0003-3841-6549
Wang, Hao http://orcid.org/0000-0001-6489-6940
He, Jin
Zheng, Lei http://orcid.org/0000-0003-4163-2541
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA169702, R01 CA197296, P01 CA247886, P50 CA062924, P30 CA006973)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 21 December 2022
Accepted: 1 June 2023
First Online: 20 June 2023
Competing interests
: L.Z. receives grant support from Bristol-Meyer Squibb, Merck, Astrazeneca, iTeos, Amgen, NovaRock, Inxmed, and Halozyme. L.Z. is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Natera, Novagenesis, Snow Lake Capitals, BioArdis, Amberstone Biosciences, Tempus, Pfizer, Tavotek Lab, ClinicalTrial Options, LLC, and Mingruizhiyao. L.Z. holds shares at Alphamab, Amberstone, and Mingruizhiyao. E.J. reports other support from Abmeta and Adventris, personal fees from Achilles, Dragonfly, Mestag, The Medical Home Group, and Surgtx, other support from Parker Institute, grants and other support from the Lustgarten Foundation, Genentech, BMS, and Break Through Cancer outside the submitted work. D.T.L. serves on advisory boards for Merck, Bristol Myers Squibb, Nouscom, G1 Therapeutics, Janssen, and Merus and has received research funding from Merck, Bristol Myers Squibb, Curegenix, Nouscom, and Abbvie. She has received speaking honoraria from Merck and is an inventor of licensed intellectual property related to technology for mismatch repair deficiency for diagnosis and therapy (WO2016077553A1) from Johns Hopkins University. The terms of these arrangements are being managed by Johns Hopkins. R.A. receives grant support from Bristol-Meyer Squibb, RAPT Theraputics. R.A. is a paid consultant for Bristol-Meyer Squibb, Merck, Astrazeneca. The remaining authors declare no other competing interests.